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REPORT
Humanized mutant FUS drives progressive
motor neuron degeneration without
aggregation in ‘FUSDelta14’ knockin mice
Anny Devoy,1 Bernadett Kalmar,2 Michelle Stewart,3 Heesoon Park,1 Beverley Burke,1
Suzanna J. Noy,1 Yushi Redhead,1 Jack Humphrey,1,4 Kitty Lo,1,4 Julian Jaeger,1 Alan Mejia
Maza,1 Prasanth Sivakumar1, Cinzia Bertolin,5 Gianni Soraru,5 Vincent Plagnol,4
Linda Greensmith,2,6 Abraham Acevedo Arozena,3,7 Adrian M. Isaacs,1,8 Benjamin Davies,9
Pietro Fratta2 and Elizabeth M. C. Fisher1
Mutations in FUS are causative for amyotrophic lateral sclerosis with a dominant mode of inheritance. In trying to model FUS-
amyotrophic lateral sclerosis (ALS) in mouse it is clear that FUS is dosage-sensitive and effects arise from overexpression per se in
transgenic strains. Novel models are required that maintain physiological levels of FUS expression and that recapitulate the human
disease—with progressive loss of motor neurons in heterozygous animals. Here, we describe a new humanized FUS-ALS mouse with a
frameshift mutation, which fulfils both criteria: the FUS Delta14 mouse. Heterozygous animals express mutant humanized FUS protein
at physiological levels and have adult onset progressive motor neuron loss and denervation of neuromuscular junctions. Additionally,
we generated a novel antibody to the unique human frameshift peptide epitope, allowing specific identification of mutant FUS only.
Using our new FUSDelta14 ALS mouse-antibody system we show that neurodegeneration occurs in the absence of FUS protein
aggregation. FUS mislocalization increases as disease progresses, and mutant FUS accumulates at the rough endoplasmic reticulum.
Further, transcriptomic analyses show progressive changes in ribosomal protein levels and mitochondrial function as early disease
stages are initiated. Thus, our new physiological mouse model has provided novel insight into the early pathogenesis of FUS-ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by pro-
gressive degeneration of motor neurons in the brain and
spinal cord, leading to muscle atrophy, paralysis and
death (Taylor et al., 2016). Although the vast majority of
ALS is sporadic (without a family history), 10% is famil-
ial; mutations in the gene FUS (fused-in-sarcoma) account
for 5% of familial and 1% sporadic ALS (Kwiatkowski
et al., 2009; Vance et al., 2009; Rademakers et al., 2010;
Nolan et al., 2016). Of the 440 mutations known in this
multi-domain protein, most cluster near or within the final
exon, which encodes the nuclear localization signal
(Dormann and Haass, 2013; Deng et al., 2014; Nolan
et al., 2016; Svetoni et al., 2016); these may be missense
or truncation mutations.
FUS binds to thousands of RNAs and regulates many
aspects of RNA biology (Ling et al., 2013; Kapeli et al.,
2016; Nolan et al., 2016; Shang and Huang, 2016; Svetoni
et al., 2016). Several mouse strains have been created to
understand FUS biology although not necessarily ALS
pathology (Nolan et al., 2016). These include knockouts,
wild-type and mutant FUS overexpressing transgenics—
including Cre-inducible and partially deleted FUS alleles.
These models give important insights into FUS function
and have shown neurons are exquisitely sensitive to FUS
gene/protein dose—thus it is unclear which aspects of neu-
rodegeneration arise from ectopic overexpression or the ef-
fects of FUS mutation (Mitchell et al., 2013; Qiu et al.,
2014; Nolan et al., 2016).
To address this key issue, we knocked into the mouse Fus
locus, the human ‘FUSDelta14’ truncation mutation asso-
ciated with ALS onset at 20 years of age and a disease
course of 22 months to death (DeJesus-Hernandez et al.,
2010). Heterozygous FUSDelta14 mice express mutant FUS
at physiological levels, which gives rise to progressive
motor neuron loss from 512 months of age in the absence
of pathological aggregation. Furthermore, we generated an
antibody to the unique carboxyl-terminus missense peptide
that arises in this human mutation, recognizing mutant FUS
only. This new powerful mouse-antibody FUS-ALS model
has allowed us to identify novel early pathological changes
involving ribosome and mitochondrial interactions at the
endoplasmic reticulum.
Materials and methods
All materials and methods can be found in the Supplementary
material.
Results
FUSDelta14 knockin mice express
mutant FUS with a unique frameshift
C-terminus at endogenous levels
To create a mouse model expressing mutant FUS at physio-
logical levels, we targeted a human frameshift mutation (FUS
p.G466VfsX14) (DeJesus-Hernandez et al., 2010) into mouse
Fus. The frameshift arises from an A to G point mutation in
the splice acceptor site of exon 14, causing skipping of exon
14 during splicing and out-of-frame translation of exon 15
(the last exon), creating a novel frame-shifted C-terminus. We
introduced the identical point mutation, g.13845A4G, into
the splice acceptor site of mouse Fus exon 14 (Fig. 1A). The
human exon 15 coding sequence was also knocked-in to
ensure the frameshift peptide produced was identical to that
of the human patient (14 residues long, Fig. 1A), because the
mouse coding sequence lacks an early stop codon and would
produce a frameshift peptide of 64 amino acids (Fig. 1B). The
new strain, B6N;B6J-Fustm1Emcf/H, is referred to as ‘FUS
Delta14’.
We assessed protein levels in spinal cord using a panel of
antibodies against wild-type and truncated frameshift
FUSDelta14 proteins (Fig. 1C). An N-terminal FUS anti-
body recognizes both, giving a single band in wild-type
and two bands in heterozygous FUSDelta14 mice. A C-ter-
minal antibody only recognizes wild-type FUS because the
epitope is lost in Delta14FUS, giving a single band in wild-
type and heterozygous FUSDelta14 mice. We generated a
novel frameshift FUS-specific antibody (fsFUS), to the last
15 residues of human FUSDelta14 frameshift protein (Fig.
1B), which specifically identifies mutant protein in hetero-
zygous FUSDelta14 mice and not wild-type FUS protein.
The N-terminal antibody was used to quantify relative
amounts of FUS in wild-type and heterozygous
FUSDelta14 spinal cord and we found no difference in
total FUS protein (Fig. 1D). However, FUSDelta14 mice
have about half as much wild-type FUS protein as their
wild-type littermates (P = 0.0168, Fig. 1E), because wild-
type and mutant alleles in FUSDelta14 heterozygotes
produce equal amounts of FUS protein (Fig. 1F). Thus
wild-type and heterozygous FUSDelta14 mice have equiva-
lent endogenous levels of FUS protein.
Heterozygous FUSDelta14 mice have
progressive motor degeneration
We carried out a broad phenotypic testing using the
International Mouse Phenotyping Consortium pipeline
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and identified progressive alterations in motor function,
which we assessed longitudinally using Locotronic (hori-
zontal ladder) and gait analysis. Compared to wild-type
littermates, at 3 months of age heterozygous FUSDelta14
mice did not show motor impairment on either test, ruling
out a developmental phenotype (Fig. 2A and B). However,
ageing FUSDelta14 heterozygotes had significant, progres-
sively increasing, Locotronic hind-limb errors (paws slip-
ping/missing rungs) at 12 and 15 months of age
(P = 0.039, Fig. 2A), but no significant difference in fore-
limb errors or time taken to complete the task
(Supplementary Fig. 1A and B). Gait analysis at 18
months showed FUSDelta14 mice have altered rear stride
pattern (not length), through a reduction in the time the
rear limb spent in the swing phase of the stride (P = 0.021;
Fig. 2B and Supplementary Fig. 1C).
A Kaplan-Meier survival analysis to 22 months of age
showed a modest but significant reduction in survival of
FUSDelta14 mice compared to wild-type littermates, from
19 months of age [LogRank(Mantel-Cox) survival
P = 0.033, Fig. 2C].
We investigated functional motor neurons innervating the
extensor digitorum hindlimb muscles, by physiological ana-
lysis of motor units. At 18 months of age motor units were
significantly reduced (15%) in FUSDelta14 extensor
digitorum compared to littermates (Mann-Whitney
Figure 1 The humanized FUS Delta14 mouse expresses endogenous levels of FUS protein. (A) Schematic of the modified FUS
locus. An A to G point mutation was introduced into the 5’ splice junction of exon 14 (red arrow) and the coding sequence of exon 15 was
converted to the human FUS sequence (red box) to ensure production of the correct frameshifted protein, as shown in B. gDNA = genomic
DNA. Protein coding sequence is shown in dark grey and untranslated regions are shown in light grey. (B) The wild-type mouse coding sequence
of exon 15 does not produce the same peptide sequence as seen in human when exon 14 is skipped due to the splicing mutation; the mouse
sequence lacks the early frameshift stop codon, and so would generate a 64-residue nonsense peptide, rather than the 14 residues for the human
frameshift peptide. The 15-amino acid peptide used to generate a frameshift FUS-specific antibody (fsFUS) matches the human frameshift
sequence. (C) Representative immunoblot from wild-type and heterozygous FUS Delta14 spinal cord showing endogenous levels of FUS protein.
The novel frameshift-FUS antibody ‘Delta14’ specifically recognizes only FUS Delta14 protein. (D–F) The N-terminal antibody was used to
quantify relative amounts of FUS in wild-type and heterozygous FUSDelta14 spinal cord. (D) No difference in total FUS protein was found
between wild-type and heterozygous FUS Delta14 mice. (E) FUS Delta14 mice have approximately half as much wild-type FUS protein as their
wild-type littermates (P = 0.0168). (F) The wild-type and mutant alleles in FUSDelta14 heterozygotes produce equal amounts of FUS protein.
Together, these results show wild-type and heterozygous FUSDelta14 mice have equivalent endogenous levels of FUS protein.
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P = 0.0022; Fig. 2D and E). To investigate whether neuro-
muscular junctions in hindlimb muscles are degenerating,
we carried out a morphological assessment of endplate
occupancy on hindlimb lumbrical muscles. In agreement
with the motor unit analysis at 18 months, intact neuro-
muscular junction numbers were significantly reduced in
heterozygous FUSDelta14 mice compared to wild-type lit-
termates (58% versus 85% fully innervated, Mann-
Whitney P = 0.028, Fig. 2F).
We counted motor neurons in lumbar spinal cord at 3,
12 and 18 months of age and found no difference between
FUSDelta14 and wild-type littermates at 3 months, again
Figure 2 FUS Delta14 mice develop progressive motor degeneration. (A) FUS Delta14 mice show a progressive increase in hindlimb
errors (missing ladder rung) during Locotronic tests (horizontal ladder). P = 0.039, n = 22 wild-type (11 males and 11 females) and 20 Delta14
mice (9 males and 11 females). (B) FUS Delta14 mice have a mild alteration in hindlimb gait by 18 months of age, with a reduced duration
of hindlimb in swing phase. P = 0.021, n = 20 wild-type (10 males and 10 females) and 19 FUS Delta14 mice (seven males and 12 females).
(C) Heterozygous FUS Delta14 mice show a small but significant reduction in lifespan. Kaplan-Meier LogRank (Mantel-Cox) survival, P = 0.033,
n = 30 wild-type (15 males and 15 females) and 30 FUS Delta14 mice (15 males and 15 females). Graph does not include deaths from general
welfare concerns associated with all inbred strains. (D) Examples of motor unit recording from extensor digitorum muscle of wild-type and
heterozygous FUS Delta14 mice at 18 months of age. (E) There are significantly fewer motor units in the extensor digitorum muscle of FUS
Delta14 mice compared to wild-type littermates. P = 0.0022, n = 6 per genotype, males only. (F) The proportion of fully innervated endplates
decreased significantly in FUS Delta14 mice compared to wild-type littermates. P = 0.028, n = 6 per genotype, males only. (G) No motor neuron
loss is observed in the L3–4 lumbar spinal cord of FUS Delta14 mice at 3 months of age, ruling out developmental differences in the lumbar motor
pool; n = 5 per genotype. (H) At 12 months of age there is a 14% loss of motor neurons in the lumbar spinal cord of FUS Delta14 mice compared
to wild-type littermates. P = 0.035, n = 5 wild-type and 7 FUS Delta14 mice. (I) By 18 months of age, 20% of motor neurons have been lost in the
lumbar spinal cord of FUS Delta14 mice compared to wild-type littermates. P = 0.006, n = 6 per genotype. Scale bar = 20mm. MN = motor
neuron.
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ruling out a developmental phenotype (Fig. 2G). However,
motor neurons were significantly decreased at 12 months
(14% reduction) and 18 months (20% reduction)
(P = 0.035 and P = 0.006, respectively; Fig. 2H and I),
which is consistent with our motor unit analysis.
FUSDelta14 protein mislocalization
to the cytoplasm increases with
disease
The FUSDelta14 mutation removes the nuclear localization
signal. We assessed the distribution of FUS protein in
lumbar spinal motor neurons by immunocytochemistry
with the C-terminal FUS antibody that detects only wild-
type FUS, and our novel mutant-specific fsFUS antibody
(Fig. 3A, and negative controls in Supplementary Fig. 2).
We found wild-type FUS is almost exclusively nuclear in
wild-type and FUSDelta14 mice at 18 months of age, with
significantly less nuclear wild-type FUS in FUSDelta14
motor neurons (P = 0.0049; Fig. 3B). We saw a trend for
increased cytoplasmic wild-type FUS in FUSDelta14 motor
neurons but this did not quite reach significance
(P = 0.0512). Interestingly, our mutant-specific antibody
showed that regardless of having no nuclear localization
signal,25% FUSDelta14 protein lies in the nucleus of
FUSDelta14 motor neurons (P5 0.0001, Fig. 3C), while
75% is cytoplasmic.
No differences in cytoplasmic:nuclear ratio were observed
between 3 and 18 months of age for the distribution of
wild-type FUS protein in wild-type mice. However, there
was a significant increase in cytoplasmic:nuclear ratio at
18 months of age for both wild-type FUS (P = 0.0062;
Fig. 3D) and mutant FUS (P = 0.0486; Fig. 3E) in hetero-
zygous FUSDelta14 mice.
FUSDelta14 protein does not
aggregate and is not depleted
from nucleus
In nucleus and cytoplasm, FUSDelta14 protein distribution
was predominantly diffuse with some perinuclear accumu-
lations. We did not observe any motor neurons that had
complete depletion of FUS protein from the nucleus. We
found no evidence of insoluble FUS (Fig. 3F) in spinal cord
lysates of 12-month-old FUSDelta14 mice (Fig. 3F)—the
youngest age that showed motor neuron loss—which
agrees with our histological observation of no aggregated
p62 and ubiquitin pathology, beyond what would be ex-
pected in aged mice (Supplementary Fig. 3). Importantly,
this suggests pathological FUS aggregates and associated
nuclear depletion of FUS do not initiate disease and do
not cause early motor neuron loss.
Human FUSDelta14 forms p62 positive cytoplasmic in-
clusions when expressed from an AAV-vector injected into
adult wild-type mouse brain (Verbeeck et al., 2012). This is
most likely explained by the protein level, because FUS
spontaneously aggregates at high concentration (Kino
et al., 2011; Shelkovnikova et al., 2014; Murakami et al.,
2015). However, to rule out that lack of aggregation path-
ology was due to differences between the partially huma-
nized mouse FUSDelta14 protein and human mutant FUS
protein, we compared the formation of stress granules. FUS
protein is recruited and accumulates in stress granules and
it has been suggested that stress granules may act as a site
for initiation/seeding of FUS aggregation (Shelkovnikova
et al., 2013; Murakami et al., 2015; Yasuda et al., 2017).
We investigated FUS recruitment to stress granules in
FUSDelta14 adult mouse fibroblasts and human primary
fibroblasts from FUS-ALS patients—including a patient
with a frameshift mutation generating the same nonsense
peptide at the C-terminus, allowing specific detection of this
protein by our fsFUS antibody. FUSDelta14 mouse fibro-
blasts had an identical response to low level induced stress
as human patient fibroblasts (Fig. 3G, H and
Supplementary Fig. 4), showing, for the first time, that
when expressed at physiological levels, mutant FUS protein
is preferentially recruited to stress granules, without wild-
type FUS. This clearly indicates that mutant FUS acts in a
gain-of-function manner with regard to stress granule for-
mation, and that our humanized mutant FUS faithfully
models human mutant FUS.
FUSDelta14 mice have disturbed
mitochondria and ribosomes
Removal and/or mutation of FUS protein disturbs RNA
metabolism, including gene expression levels. To investigate
the impact of FUSDelta14 on the transcriptome we carried
out longitudinal RNAseq on lumbar spinal cord. In hetero-
zygous FUSDelta14 mice at the 3-month asymptomatic age,
we identified only three genes with altered expression (Fig.
4A and Supplementary Table 1). However, by 12 months
of age heterozygous FUSDelta14 mice have 1289 dysregu-
lated genes (Fig. 4B and Supplementary Table 2), predom-
inantly showing decreased expression. Gene ontology (GO)
analysis and Gene Set Enrichment Analysis (GSEA) identi-
fied genes encoding mitochondrial proteins, ribosomal pro-
teins and the catalytic core of the proteasome as
significantly enriched in the list of dysregulated genes
(Fig. 4C, Supplementary Fig. 5 and Supplementary Tables
3–10). A number of dysregulated genes were validated at
the protein level. Interestingly, while gene expression was
down protein levels were up (Supplementary Fig. 6), sug-
gesting the possibility that an increase in proteins may be
driving the gene downregulation.
We noticed that the perinuclear accumulations of mutant
FUSDelta14 (Fig. 3A) bear a striking resemblance to Nissl
substance, which stains the rough endoplasmic reticulum
(RER), an area of dense accumulation of ribosomes and
mitochondria. We confirmed that the cytoplasmic accumu-
lations of FUSDelta14 protein overlap RER by co-localiza-
tion with S6 riboprotein (Pearson correlation 0.415;






/brain/article/140/11/2797/4372144 by guest on 01 M
arch 2021
Figure 3 FUS Delta14 protein mislocalizes to the cytoplasm but does not aggregate. (A) Using a C-terminal FUS antibody that
detects only wild-type FUS (magenta) and our novel mutant-specific FUS antibody (fsFUS, white) to quantify the distribution of FUS protein in
lumbar motor neurons. Perinuclear accumulations of fsFUS are observed (arrow). (B) Quantification of distribution of wild-type FUS protein in
the nucleus versus cytoplasm of motor neurons in wild-type versus heterozygous FUS Delta14 mice. Wild-type FUS is located almost exclusively
in the nucleus in both wild-type and FUS Delta14 mice, with significantly less nuclear wild-type FUS in FUS Delta14 motor neurons (P = 0.0049).
(C) Quantification of distribution of FUS Delta14 protein in the nucleus versus cytoplasm of motor neurons in heterozygous FUS Delta14 mice.
There is significantly more cytoplasmic FUS Delta14 protein compared to nuclear protein, although 25% of FUS Delta14 protein is nuclear in spite
of the lack of the nuclear localization signal (P5 0.0001). The distribution of FUS changes with age in Delta14 mice. (D) No differences in the
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Fig. 4D), indicating that mutant FUS may directly contrib-
ute to early ribosome and mitochondrial alterations.
Discussion
Here we describe the first mouse model to fully recapitulate
human FUS-ALS, as defined by midlife-onset (512 months
of age) progressive degeneration of motor neurons with a
dominant mode of inheritance. Crucially, we express huma-
nized mutant FUS from the endogenous mouse Fus locus
and both mRNA and protein are expressed at endogenous
levels. By behavioural analysis of motor performance,
muscle physiology to assess innervation and function of
hindlimb muscles, and pathological analysis of spinal
motor neurons, the FUSDelta14 mouse has a consistent
clinical picture of dominantly inherited, adult-onset, pro-
gressive degeneration of motor neurons.
Recently, Scekic-Zahirovic et al. (2017) generated hetero-
zygous knockin mice expressing a reversible Fus nuclear
localization signal-deletion allele, which have late-onset
motor neuron loss at 22 months of age, that importantly,
is rescued by selective expression of wild-type Fus in motor
neurons. Importantly, heterozygous knock-out mice in the
same study did not lose motor neurons, providing the
strongest evidence to date that it is a gain-of-function
through mislocalization, not loss of function that leads to
motor neuron death. In contrast, our FUSDelta14 mice de-
velop motor neuron loss considerably earlier by 12 months
of age. The reason for this difference is not clear, but as
FUSDelta14 mice have a normal motor system in young
adulthood (3 months of age) and motor neuron loss is
clearly underway by 12 months, this gives us an excellent
window in which to investigate early pathomechanisms.
This is an important issue for understanding ALS, as we
do not know when the disease begins and have limited
biomarkers for disease progression. Already, our work
has shown that while pathological aggregation of FUS pro-
tein in not required for the initiation of disease and motor
neuron death, there is clear evidence of disturbed
proteostasis.
In FUS-ALS motor neuron loss is primarily driven by a
gain-of-function mechanism (Scekic-Zahirovic et al., 2016,
2017; Sharma et al., 2016; Shiihashi et al., 2016), and the
focus has been on cytoplasmic gain-of-function because
mutant FUS is mislocalized and the level of mislocalization
has been linked to disease severity (Bosco et al., 2010;
Dormann et al., 2010; Higelin et al., 2016). We observe
an increase in cytoplasmic mislocalization of FUS as disease
progresses. However, interestingly, we do not observe nu-
clear depletion of FUS and using our FUSDelta14 antibody,
we show that in heterozygous FUSDelta14 mice 25%
FUSDelta14 protein is nuclear, despite the lack of a nuclear
localization signal. We also observed nuclear fsFUS in both
our mouse and human fibroblast lines. Thus toxic gain-of-
functions may occur in both the nucleus and cytoplasm.
One clear gain-of-function that we observed was almost
exclusive recruitment of mutant FUS to stress granules,
using our novel mutant FUS-specific antibody, showing
clearly for the first time that wild-type FUS has limited
recruitment when expressed at physiological levels.
Importantly, we found complete correlation between our
FUSDelta14 fibroblasts and human FUS-ALS fibroblasts,
highlighting that the behaviour of mutant FUS protein is
consistent between mouse and human.
Our RNAseq results agree with a toxic gain-of-function:
FUSDelta14 showed few alterations in gene expression at
an asymptomatic age (3 months) in contrast to knockdown/
knockout studies (Lagier-Tourenne et al., 2012; Colombrita
et al., 2015). At a symptomatic time point (12 months)
gene expression was dramatically dysregulated. The path-
ways over-represented are translation (ribosomes), energy
metabolism (mitochondria) and protein turnover (prote-
asome) and, with protein levels also dysregulated, may
highlight disturbed proteostasis as a key early disease
stage. Importantly, we identified FUSDelta14 protein accu-
mulates at the RER, which is a key location for the inter-
action between these pathways, suggesting a potential
pathomechanism and site of action.
Our data suggest the FUS-ALS toxic gain-of-function
occurs in cytoplasm and/or nucleus, in the absence of ag-
gregation. The FUSDelta14 mouse-antibody allows us to
map molecular changes longitudinally, from early develop-
ment to humane end stage, in an in vivo physiological
model, and to investigate mutant-specific interactions with
Figure 3 Continued
cytoplasmic:nuclear ratio were observed between 3 and 18 months of age for the distribution of wild-type FUS protein in wild-type mice.
However, there was a significant increase in the cytoplasmic:nuclear ratio of wild-type FUS protein in heterozygous FUS Delta14 mice
(P = 0.0062). (E) There is an increase in cytoplasmic:nuclear ratio of mutant FUS protein at 18 months of age in heterozygous FUS Delta14 mice
(P = 0.0486). (F) There is no insoluble FUS protein present in the lumbar spinal cord of 12-month-old wild-type and heterozygous FUS Delta14
mice. SOD1 G93A spinal cord was used as a positive control (data not shown). Mutant FUS protein is preferentially recruited into stress granules.
(G) In wild-type and heterozygous adult mouse fibroblasts almost no wild-type FUS protein (wtFUS, magenta) is detected in cytoplasmic stress
granules. However, in heterozygous FUS Delta14 fibroblasts a significant proportion of cytoplasmic frameshift FUS protein (fsFUS, white) co-
localizes with the stress granule marker G3BP, green. (H) Human fibroblasts with a frameshift mutation in FUS (G496Gfs), which have the same
frameshift peptide sequence at the C-terminus that is recognized by our novel frameshift FUS antibody (fsFUS, white), show the same recruitment
of cytoplasmic frameshift FUS protein to stress granules (G3BP, green) as observed in FUS Delta14 adult mouse fibroblasts. Recruitment of wild-
type FUS protein to stress granules is limited (wtFUS, magenta). Scale bar = 20 mm.
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our novel antibody. This system is a powerful tool and is
giving new insight into early stages of ALS.
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